Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant tre...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of international medical research Vol. 44; no. 1_suppl; pp. 67 - 71
Main Authors:	De Simone, Clara, Perino, Francesca, Caldarola, Giacomo, D’Agostino, Magda, Peris, Ketty
Format:	Journal Article
Language:	English
Published:	London, England SAGE Publications 01.09.2016
Subjects:	Immuno-Mediated Diseases And Comorbities Antitumour necrosis factor-α agents psoriatic arthritis comorbidities etanercept psoriasis
ISSN:	0300-0605, 1473-2300, 1473-2300
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0300-0605 1473-2300 1473-2300
DOI:	10.1177/0300060515593250